CN Patent

CN121399123A — 作为突变型kras g12c抑制剂用于治疗癌症的吡啶并[4,3-d]嘧啶衍生物

Assigned to Frontier Pharmaceuticals · Expires 2026-01-23 · 0y expired

What this patent protects

本公开提供了用于治疗和抑制癌症，例如可用于治疗或抑制癌症KRAS G12C的式(I)至(VII)的化合物。还提供了含有此类化合物的药物制剂和用于制备此类化合物的方法。

USPTO Abstract

本公开提供了用于治疗和抑制癌症，例如可用于治疗或抑制癌症KRAS G12C的式(I)至(VII)的化合物。还提供了含有此类化合物的药物制剂和用于制备此类化合物的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN121399123A
Jurisdiction
CN
Classification
—
Expires
2026-01-23
Drug substance claim
No
Drug product claim
No
Assignee
Frontier Pharmaceuticals
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.